The synthesis of some novel 3′-spirocyclic-oxindole compounds, based on the spiro[indole-3,5′-isoxazolidin]-2(1H)-one, the 2′H-spiro [indole-3,6′-[1,3]oxazinane]-2,2′(1H)-dione and the 2′H-spiro[indoline-3,3′-pyrrolo[1,2-c][1,3′]oxazine]-1′,2(1H)-dione heterocyclic structures, is described. These compounds were prepared from methyl α-(2-nitrophenyl)acrylate via [1, 3] -dipolar cycloaddition reactions with two acyclic nitrones and one cyclic nitrone followed by reduction of the cycloadducts and then treatment with triphosgene. Two of these compounds showed significant cytostatic activity on three cancer cell lines with GI 50 values of 2.6-4.1 μM on the human breast cancer cell line, MCF-7. 
Introduction
3'-Spirocyclo-oxindoles, of synthetic or natural origin, have a range of biological activities. 1 As part of a medicinal chemistry project we have been focusing on the synthesis of novel 3'-spirocyclo-oxindoles as scaffolds for new drug discovery. 2, 3 As an extension of this project we required the synthesis of the novel 3'-spirocyclic-oxindoles of the type B and D. These were planned to be accessed from the isoxazoline intermediate A which in principle could be formed via a [1, 3] -dipolar cycloaddition reaction between the acrylate 1 [2] [3] [4] and nitrones. Regioselective reduction of A would provide isoxazolidine spirocyclic oxindoles B, while further reduction would provide the amino-alcohol C which upon treatment with phosgene, or its equivalent, was expected to provide oxazinane spirocyclic oxindoles of the type D (Scheme 1). and Schreiber 6 have earlier described [1, 3] -dipolar cycloadditions of azomethine ylides to 2a (R = CO 2 Et, aryl and CO 2 allyl) and their 5-and 6-substituted derivatives to provide novel spirocyclic structures. Some of these were found to be a new class of non-peptide, small molecule MDM2-p53 inhibitors, a relatively new target for cancer chemotherapy.
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In 1998, Melot 7 reported the synthesis of isoxazolidine spirocyclic isoindolines, compounds isomeric to B, using a nitrone cycloaddition reaction of 3-methyleneisoindolines 2b. We report here our efforts for preparing novel spirocycles related to B and D and their stereochemistries and the cytostatic activities of some of these compounds against three cancer-cell lines.
Results and Discussion
Initial investigations on the [1, 3] -dipolar cycloaddition of 1 with nitrones involved a study of the reaction of 1 and the nitrone 3a. Heating a dichloromethane solution of 1 and 3a (1.1 molar equiv.)
at 60 o C in a sealed tube for 4 d resulted in a mixture of 1, 4a and 5a, from which pure samples of 4a and 5a could be isolated in yields of 26% and 20%, respectively after purification by column chromatography (Scheme 2). Heating a mixture of 1 and 3a (1.1-1.2 molar equiv.) at 150 o C in a microwave reactor in toluene solution, or in the absence of solvent, for 30 min resulted in the isolation of pure samples of 1, 4a and 5a, in yields of 29%, 15% and 30%, respectively. In each case unreacted dipolarophile (1) was isolated. When pure cycloadduct 4a was heated at 150 o C in a microwave reactor without solvent for 30 min, a 42 : 30 : 28 mixture of 1, 4a and 5a, respectively, was produced. This experiment clearly demonstrated the reversible nature of the cycloaddition reaction between 1 and 3a and also helped to explain the lack of complete consumption of the dipolarophile in these reactions. We assume that the nitrone 3a was also generated in this experiment but it could not be detected from . Separation of this mixture by column chromatography gave pure samples of 7 and 8, in yields of 40%, and 6%, respectively and a mixture of 1 and 8 that was difficult to separate. 1 H NMR analysis clearly indicated that 7 and 8 were both pyrrolo [1,2-b] isoxazole-2-carboxylate regioisomers (with the expected three proton coupled spin system of H-3a and H-3 and H-3 clearly evident). The relative stereochemistry of these adducts was assigned based on NOESY studies. These studies showed cross-peaks between H O and the most upfield H-3 proton (H-3) for both compounds 7 and 8 while cross-peaks were observed between H-3a and H-3 in 7 and between H-3a and H-3 (in C 6 D 6 ) in 8. This analysis indicated that 7 was the endo-isomer and 8 the exo-isomer. 11a (61%, 3 days), 11b (68%, 2 days).
attempts at the hydrogenation of 7 or 8 over 10% Pd/C or the reduction of these compounds with zinc dust in glacial acetic acid under sonication conditions gave rise to complex reaction mixtures.
However, hydrogenation/hydrogenolysis of 8 over PdCl 2 in methanol followed by treatment of the crude reaction mixture with triphosgene/Et 3 N gave the desired tetracyclic spiro compound 16 in 25% overall yield (Scheme 6). days, 25% overall from 8.
Cytostaticity Studies
Cytostaticity studies against the cancer cell lines, H460 (human non small cell lung), MCF-7
(human breast) and SF-268 (human CNS) were performed at the Peter MacCallum Cancer Institute, Melbourne, Australia, using standard NCI protocols. Initially the percentage cell growth of cells incubated with 25 M of compounds 4a, 7, 9, 10b, 11a, 11b and 14 was measured after 72 h. The results are presented in Table 1 . The initial screening indicated that only compounds 7 and 9 had an appreciable cytostatic activity against all three cell lines at 25 M (Table 1, suggest that it has a narrow therapeutic index, that is there is a fineline between no activity and high toxicity. Furthermore at higher doses of 9, cytotoxicity as opposed to cytostaticity was clearly demonstrated as fewer cells remained at the end of the assay than when at the beginning.
Interestingly, while the isoxazolidine spirocyclic isoindoline 9 had the most cytostatic activity, its ring expanded analogues, 11a,b having an oxazinane ring rather than a isoxazolidine showed little activity. This may be a function of the differences in ring size (5 versus 6) and/or the basicity of the respective nitrogen atoms.
In conclusion, the synthesis of some novel 3'-spirocyclic-oxindole compounds, based on the mol, 40%). 
Methyl (3`R*, 5`R*)-5`-(2-nitrophenyl)-2`,3`-diphenylisoxazolidine-5`-carboxylate (4b) and

Methyl (3`S*, 5`R*)-5`-(2-nitrophenyl)-2`,3`-diphenylisoxazolidine-5`-carboxylate (5b)
7: MS (EI) m/z
2`-Methyl-(3`S*, 5`R*)-3`-phenylspiro[indole-3,5`-isoxazolidin]-2(1H)-one (9)
To a solution of 4a (54 mg, 
(2R*, 3R*)-3-Hydroxy-3-[2-(methylamino)-2-phenylethyl]-1,3-dihydro-2H-indol-2-one (10a)
To a solution of 4a (78. 
(2R*, 3S*)-3-(2-Anilino-2-phenylethyl)-3-hydroxy-1,3-dihydro-2H-indol-2-one (10b)
The title compound was prepared using two methods. 
2`-Methyl-(3`R*, 5`R*)-3`-phenylspiro[indole-3,5`-isoxazolidin]-2(1H)-one (12)
The title compound was prepared from 5a (78 mg, 2.3  10 -4 mol) using a similar method to that described above for the preparation of 9. However, the reaction was left for only 2 h. The crude product was purified by column chromatography using 30-50% EtOAc in petrol to yield 12 as a yellow oil (34. 3S*)-3-hydroxy-3-[2-(methylamino)-2-phenylethyl]-1,3-dihydro-2H-indol-2-one (13) The title compound was prepared from 5a (49 mg, 1.43  10 -4 mol) using a similar method to that described above for the synthesis of 10a. The title compound was prepared from 10b (20.9 mg, 6.1  10 -5 mol) using a similar method to that described above for the synthesis of 11a. However, the reaction was left for only 2 d. The crude product was then purified by column chromatography using 30-100% 
3`-Methyl-(4`S*, 6`R*)-4`-phenyl-2`H-spiro[indole-3,6`-[1,3]oxazinane]-2,2`(1H)-dione (14)
The title compound was prepared from 13 (41.8 mg, 1.5  10 -4 mol) using a similar method to that described above for the synthesis of 11a. However, the reaction was left for only 2 d. mol, 25% over 2 steps). Figure. GI 50 curves in duplicate for 9 ((A) and B)) and 7 ((C) and D)) against a MCF-7 cell line. 
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